Weight loss medications in the UK are governed by multiple regulatory bodies working together to ensure patient safety. Understanding this framework helps you make informed decisions about your treatment and identify legitimate providers.
Key Regulatory Bodies
- MHRA (Medicines and Healthcare products Regulatory Agency): Approves medications for use in the UK, monitors safety, and can withdraw products if safety concerns emerge.
- NICE (National Institute for Health and Care Excellence): Evaluates the clinical and cost-effectiveness of treatments and issues guidance on NHS usage.
- GPhC (General Pharmaceutical Council): Regulates pharmacies and pharmacy professionals in England, Scotland, and Wales.
- CQC (Care Quality Commission): Regulates healthcare services in England, including private clinics that prescribe weight loss medications.
- GMC (General Medical Council): Regulates doctors, including those who prescribe in online settings.
Prescribing Rules for Weight Loss Medications
In the UK, weight loss medications like Mounjaro are prescription-only medicines (POM). This means they can only be legally supplied following a valid prescription from an authorised prescriber. The prescriber must:
- Conduct an adequate clinical assessment
- Confirm the patient meets eligibility criteria
- Check for contraindications and drug interactions
- Provide appropriate follow-up care
- Maintain proper clinical records
Who Can Prescribe?
In the UK, Mounjaro can be prescribed by:
- Doctors (GPs and specialists) registered with the GMC
- Independent prescriber pharmacists who have completed additional prescribing qualifications and are registered with the GPhC
- Nurse independent prescribers registered with the NMC
Recent Regulatory Changes
The UK regulatory environment has seen significant developments in recent years:
- Reclassification discussions: There have been ongoing discussions about potentially reclassifying certain weight loss medications to make them more accessible, similar to how Wegovy was briefly considered for pharmacy-only supply.
- Increased enforcement: The MHRA has stepped up enforcement against websites selling prescription medications without proper authorisation, seizing counterfeit GLP-1 products.
- Compounding restrictions: The MHRA has issued guidance restricting the use of compounded (non-branded) semaglutide and tirzepatide, directing patients toward approved branded products.
- Advertising standards: The ASA (Advertising Standards Authority) has tightened rules on how weight loss medications can be marketed to the public.
Your Rights as a Patient
Under UK regulations, you have the right to:
- Know the qualifications of the person prescribing your medication
- Access your medical records held by the pharmacy
- Raise complaints through the pharmacy's formal complaints procedure or directly to the GPhC
- Report suspected counterfeit medication to the MHRA Yellow Card scheme
Staying informed about regulations protects you and ensures you receive safe, effective treatment.